Dr. Aneal Khan, Genetics | Alethea Medical

Dr. Aneal Khan

Claim this profile

MAGIC Clinic Ltd

Studies Fabry Disease
Studies Hunter Syndrome
9 reported clinical trials
10 drugs studied

Area of expertise

1Fabry Disease
Aneal Khan has run 3 trials for Fabry Disease.
2Hunter Syndrome
Aneal Khan has run 2 trials for Hunter Syndrome. Some of their research focus areas include:
I2S
GAGs
IDS

Affiliated Hospitals

Image of trial facility.
M.A.G.I.C. Clinic Ltd.
Image of trial facility.
Metabolics And Genetics In Calgary (MAGIC) Clinic, Ltd.

Clinical Trials Aneal Khan is currently running

Image of trial facility.

PTC923

for Phenylketonuria

This trial is testing the safety of a medication called PTC923 in people with phenylketonuria (PKU). PKU patients need to manage their blood phenylalanine levels carefully. PTC923 aims to help control these levels, making it easier for patients to manage their condition. PTC923 is a newer treatment for PKU, following earlier treatments like sapropterin and pegvaliase.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Registry

for Fabry Disease

CFDI NATIONAL REGISTRY Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic pain, kidney disease, heart disease, stroke and/or premature death; often before the age of 60. Fabry Disease is estimated to affect approximately one out of every 40,000 males and up to twice as many females in Canada. We do not have the exact number of persons in Canada who have this disease. A common problem in studying rare conditions is the difficulty in identifying the majority of people suffering from such a disease. Gathering their health information in order to better understand the natural disease progression and its response to treatment is difficult. Early ERT studies involving humans had small numbers of subjects and the studies were of short duration. The results of these clinical studies did lead to approval of the therapy in many countries around the world including Canada. To date though, evidence of the usefulness of ERT and its direct impact on the natural course of Fabry disease has been limited, while its cost continues to be very high. As a result of these issues, there will need to be continued and long-term collection of information related to the effectiveness of ERT and other treatments to better document its true clinical outcomes in Canadian people with Fabry disease. The Canadian Fabry Disease Initiative National Registry (CFDI-NR) is an observational, voluntary registry designed to collect outcomes data on Fabry disease from people living in Canada.
Recruiting1 award N/A5 criteria

More about Aneal Khan

Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Aneal Khan has experience with
  • Placebo
  • PTC923
  • GTX-102
  • AVR-RD-02
  • AVR-RD-01
  • Enzyme Replacement Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Aneal Khan specialize in?
Is Aneal Khan currently recruiting for clinical trials?
Are there any treatments that Aneal Khan has studied deeply?
What is the best way to schedule an appointment with Aneal Khan?
What is the office address of Aneal Khan?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security